ReviewCurrent medicinal chemistry2007
Therapeutic targets in the ARF tumor suppressor pathway.
Review in Current medicinal chemistry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Opportunities in cancer gene therapy: inhibiting MDM2 and restoring p14ARF as a means to activate p53.Molecular and cellular biochemistry · 2026Review
- Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma.Frontiers in oncology · 2022Review
- Regulation of p53 by E3s.Cancers · 2021Review
- c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis.Nature communications · 2020Article
- The p14ARF tumor suppressor restrains androgen receptor activity and prevents apoptosis in prostate cancer cells.Cancer letters · 2020Article
- Dual Role of the Alternative Reading Frame ARF Protein in Cancer.Biomolecules · 2019Review
- Reviving the guardian of the genome: Small molecule activators of p53.Pharmacology & therapeutics · 2017Review
- CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.Oncogene · 2016Review
- Transcription factors that interact with p53 and Mdm2.International journal of cancer · 2016Review
- Article
- ARF and p53 coordinate tumor suppression of an oncogenic IFN-β-STAT1-ISG15 signaling axis.Cell reports · 2014Article
- ARF: a versatile DNA damage response ally at the crossroads of development and tumorigenesis.Frontiers in genetics · 2014Article
- A conserved domain in exon 2 coding for the human and murine ARF tumor suppressor protein is required for autophagy induction.Autophagy · 2013Article
- Differential effects on ARF stability by normal versus oncogenic levels of c-Myc expression.Molecular cell · 2013Article
- Molecular pathways undergoing dramatic transcriptomic changes during tumor development in the human colon.BMC cancer · 2012Article
- Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal stresses.Cell death and differentiation · 2012Article
- ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model.The Journal of pathology · 2012Article
- Hypergrowth mTORC1 signals translationally activate the ARF tumor suppressor checkpoint.Molecular and cellular biology · 2012Article
- RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.Nature reviews. Cancer · 2011Review
- The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice.PloS one · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
One of the outstanding fundamental questions in cancer cell biology concerns how cells coordinate cellular growth (or macromolecular synthesis) with cell cycle progression and mitosis. Intuitively, rapidly dividing cells must have some control over these processes; otherwise cells would continue to shrink in volume with every passing cycle, similar to the cytoreductive divisions seen in the very early stages of embryogenesis. The problem is easily solved in unicellular organisms, such as yeast, as their growth rates are entirely dependent on nutrient availability. Multicellular organisms such as mammals, however, must have acquired additional levels of control, as nutrient availability is seldom an issue and the organism has a prodigious capacity to store necessary metabolites in the form of glycogen, lipids, and protein. Furthermore, the specific needs and specialized architecture of tissues must constrain growth for growth's sake; if not, the necessary function of the organ could be lost. While certainly a myriad of mechanisms for preventing this exist via initiating cell death (e.g. apoptosis, autophagy, necrosis), these all depend on some external cue, such as death signals, hypoxia, lack of nutrients or survival signals. However there must also be some cell autonomous method for surveying against inappropriate growth signals (such as oncogenic stress) that occur in a stochastic fashion, possibly as a result of random mutations. The ARF tumor suppressor seems to fulfill that role, as its expression is near undetectable in normal tissues, yet is potently induced by oncogenic stress (such as overexpression of oncogenic Ras or myc). As a result of induced expression of ARF, the tumor suppressor protein p53 is stabilized and promotes cell cycle arrest. Mutations or epigenetic alterations of the INK4a/Arf locus are second only to p53 mutations in cancer cells, and in some cancers, alterations in both Arf and p53 observed, suggesting that these two tumor suppressors act coordinately to prevent unwarranted cell growth and proliferation. The aim of this review is to characterize the current knowledge in the field about both p53-dependent and independent functions of ARF as well as to summarize the present models for how ARF might control rates of cell proliferation and/or macromolecular synthesis. We will discuss potential therapeutic targets in the ARF pathway, and some preliminary attempts at enhancing or restoring the activity of this important tumor suppressor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.